Archive for 'Healthcare consulting' Category:

2798315677_c07935c8da_o
By Ben Zwillinger: Wednesday 9th March, 2016

How to Use Human Nature to Your Advantage During User Testing

During Human Factors studies we often ask participants to complete a series of tasks designed to be representative of the normal use process. Many times participants do not act consistently. Perhaps a participant acts one way during the first task, but differently during the following task. Or, a participant answers questions indicating the opposite of […]

weighing machine from a sea pebble
By Dean Griffiths: Tuesday 2nd June, 2015

Supplying the demand for precision medicine

Supply and demand is one of the fundamental concepts in economics; in a market economy supply and demand theory suggests resources will be allocated in the most efficient way possible.  The inexorable rise in the demand for healthcare and the ever-increasing costs associated with the supply of new therapies has meant that understandably, a true […]

Analyzing
By Sam Pooley: Friday 29th May, 2015

Look, no hands!

The streets of the UK are to become the testing arena for three separate trials of next generation driverless car.  Backed by £19m of government funding, the trials aim to position the UK as a world leader in what is expected to be a £900bn industry by 2025.  Whilst the prospect of driverless cars is in itself […]

Innovative technology
By Dean Griffiths: Tuesday 3rd March, 2015

Three innovation trends in life sciences

Successful products meet the needs of customers; brands including Apple, Gucci and Porsche can create needs, however for most brands, successful products delight customers by fulfilling pre-existing unmet needs. The diversity of needs across the life sciences research market is significant.  Researchers are looking to uncover the molecular mechanisms underpinning questions which vary from neurodegeneration, […]

Neurons and nervous system
By Sam Pooley: Tuesday 20th January, 2015

Aptamers – the optimum selection for the future?

Novartis recently cleared an important FDA hurdle with its pioneering biosimilar of Amgen’s Neupogen; paving the way for the first U.S. approval of a biosimilar drug.  Pharmaceutical and biotech drugs have been fighting both for and against the introduction of biosimilars to challenge the market position of biologics.  There is a third player which over […]

data flow
By Dean Griffiths: Tuesday 13th January, 2015

Product bundling for DNA sequencing

Roche recently announced that they have made another move in the DNA sequencing space; Roche will spend $1.03 billion to buy a 56.3% stake in Foundation Medicine. This comes after other recent moves which have seen Roche acquire Genia Technologies and Ariosa Diagnostics. In growing its’ portfolio Roche is highlighting the importance of two things; […]

DNA
By Dean Griffiths: Monday 2nd June, 2014

Sequencing; will DNA analysis have any other name?

The analysis of nucleic acids is increasingly at the heart of the care pathway for patients with a myriad of different diseases.  Diagnosis of many diseases from cancer to flu increasingly relies upon an analysis of the nucleic acids present in a sample.  The question I get asked most frequently when I talk with in […]

Drug Delivery
By Dean Griffiths: Friday 23rd May, 2014

Cancer therapies; cost, price and value

A plethora of data demonstrating the efficacy of new cancer therapies will be released at the upcoming American Society for Clinical Oncology (ASCO).  Data are expected from Roche, Merck, Bristol-Myers Squibb about their immuno-oncology therapies but the most hotly debated topic may be the introduction of an ASCO scorecard which will rate therapies not just […]

Single cell balance
By Dean Griffiths: Thursday 15th May, 2014

Single cell analysis; learning more from individuals than crowds

Genomics, proteomics, transcriptomics, epigenomics and many others large scale tools have been driving the economics of life science research for a number of years.  These technologies have provided insight into many of the mechanisms which control how cells and tissues function.  However these technologies are often hindered by their requirements for a large quantity of […]

immunology
By Dean Griffiths: Wednesday 19th February, 2014

Cancer immunotherapies; which silver bullet?

Novartis this week further committed to cancer immunotherapy with the acquisition of CoStim; increasing the number of major players looking to cancer immunotherapies as the next wave of cancer treatments.  With Novartis, Merck and Bristol-Myers Squibb and Roche all working in the same space, will efficacy alone be sufficient to capture significant market share? Modulation […]

Media


Recent Posts


Posts by categories